GSK2110183
Проводит ГлаксоСмитКляйн ЛЛС
Страница компанииОткрытое исследование I/II фазы по изучению препарата GSK2110183 в комбинации с карбоплатином и паклитакселом для пациентов с резистентным к препаратам платины раком яичников
Постоянная ссылка: https://clinomir.ru/trials/permit/ru/51/2013-01-21/
Источник: ГРЛС — Государственный реестр лекарственных средств Минздрава России; ClinicalTrials.gov (U.S. National Library of Medicine); clinmarket. Что откуда
Простыми словами
Словарь терминов- Фаза II — препарат уже прошёл первую проверку безопасности. Проверяют, действует ли он при этом заболевании, и уточняют дозу.
- Исследование завершено, новых участников не набирают.
- Возраст участников: от 18 лет, только женщины. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 30 чел. в стране «Россия».
- Центров в реестре: 3 в 3 городах. Список — ниже на странице.
- Плановая дата окончания (01.2016) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- Опухольнужен измеримый очаг (RECIST)
- Стадияметастатическая (IV)
- ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 23 · невключение: 23
Критерии включения
- Phase I Inclusion Criteria:
- Female, 18 years of age as of signing the informed consent form, capable of giving/complying with written informed consent
- Histologically or cytologically confirmed serous ovarian cancer (includes primary peritoneal and Fallopian tube)
- Negative serum pregnancy test in women of childbearing potential within 14 days of first dose of treatment, agree to use effective contraception during/after (6 months post dose of paclitaxel or 30 days post dose GSK2110183 whichever is longer)
- Performance Status score of 0-2 according to the ECOG scale.
- Able to swallow and retain oral medication
- Subjects diagnosed previously with Type 2 diabetes must have been diagnosed ≥ 6 months prior to enrollment
- Prior treatment-related toxicities (except for alopecia) must be ≤ Grade 1 according to NCI-CTCAE (Version 4.0 \[NCI, 2009\]) at the time of treatment allocation OR ≤ Grade 2 and stable for 4 weeks or longer at the time of screening evaluation. Exception: Subjects with peripheral neuropathy >/= Grade 2 will NOT be eligible
- Adequate organ system function
- Phase II Inclusion Criteria:
- Cohort A
- Phase I criteria
- Documented complete or partial response by RECIST to at least 1 prior platinum-based therapy
- Progression defined by either (1) RECIST v1.1 criteria or (2) GCIG CA 125 criteria associated with symptoms necessitating treatment between 1 and 6 months of prior platinum-based therapy either in adjuvant or metastatic setting
- Subjects allowed to have a maximum of one non-platinum-based therapy between the onset of platinum resistance
- Must have radiologically measurable disease i.e. presenting with at least one measurable lesion per RECIST 1.1
- Cohort B
- Phase I criteria
- Documented complete or partial response by RECIST to at least 1 prior platinum-based therapy
- Progression defined by either (1) RECIST v1.1 criteria or (2) GCIG CA 125 criteria associated with symptoms necessitating treatment while being treated with a regimen containing carboplatin and paclitaxel (or within 4 weeks of completing treatment)
- Subjects will be required to start on treatment within 8 weeks after the last infusion of chemotherapy and may not have had any other anti-cancer therapy in the intervening time
- Must have radiologically measurable disease i.e. presenting with at least one measurable lesion per RECIST 1.1
- Additional restrictions on number of prior therapies may be added to eligibility criteria based on emerging data
Критерии невключения
- History of another malignancy (some exceptions may apply)
- Serious and/or unstable pre-existing medical or psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures
- Current use of prohibited medication during treatment.
- Chemotherapy, immunotherapy, or other anti-cancer therapy within 14 days prior to the first dose study drug
- Radiotherapy prior to initiation of therapy (some exceptions may apply)
- Contraindications (identified by the investigator) to the doses of carboplatin and/or paclitaxel
- History of reduction in standard of care paclitaxel dose for peripheral neuropathy
- No known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to drugs similar or related to GSK2110183
- No known delayed hypersensitivity reaction or idiosyncratic reaction to drugs similar to carboplatin or paclitaxel (some exceptions may apply)
- Prior use of a drug that targets AKT including perifosine
- History of Type 1 diabetes
- Gastrointestinal disease or other condition that could affect absorption or predispose subject to gastrointestinal ulceration
- Mucosal or internal bleeding
- Major surgery within the last four weeks
- Infection requiring parenteral or oral anti-infective treatment
- Severe or uncontrolled systemic diseases
- Brain metastases and/or leptomeningeal disease
- QTcF interval ≥ 470 msecs
- Bundle branch block, pacemaker or clinically significant ECG abnormalities including 2nd degree (Type II) or 3rd degree atrioventricular (AV) block
- History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty,stenting or bypass grafting within six months of Screening
- Class II, III or IV heart failure as defined by the NYHA functional classification system
- Pregnant or lactating female
- Malignancies related to HIV or solid organ transplant; history of known HIV, history of know HBV surface antigen positivity (subjects with documented laboratory evidence of HBV clearance may be enrolled) or positive HCV antibody
Источник: ClinicalTrials.gov, NCT01653912 · запись обновлена в реестре 2 апреля 2018.
Дизайн и результаты
Что измеряют — первичные конечные точки (5), вторичных — 6
- Phase 1: Number of Subjects With Treatment-Emergent Adverse Events (TEAE) of Grade Greater Than or Equal to (≥) 3 in Severity — Up to Week 3
- Phase 1 Safety: Number of Subjects Reporting Adverse Events — Up to Week 3
- Phase 1: Maximum Tolerated Dose (MTD) of GSK2110183 — Up to Week 3
- Overall Response Rate (ORR) in Phase 2 Subjects With Recurrent Platinum-resistant Ovarian Cancer (Cohort A) — Every 3 weeks up to 6 months
- ORR in Phase 2 Subjects With Recurrent Platinum-refractory Ovarian Cancer (Cohort B) — Every 3 weeks up to 6 months
Цель исследования
* Dose-finding study of GSK2110183 administered in combination with carboplatin and paclitaxel to any subject with recurrent ovarian cancer.
* Safety and efficacy study of GSK2110183 administered in combination with carboplatin and paclitaxel to subjects with platinum-resistant ovarian cancer.
Области и заболевания
Где проходит
3 центра в 3 городахОткуда эта информация
-
ГРЛС — Государственный реестр лекарственных средств Минздрава России · № 51 от 21.01.2013 Официальный реестр · загружено 1 октября 2026Препарат, номер протокола, название, разрешение, фаза, сроки, число участников, спонсор, разработчик
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT01653912 Официальный реестр (США) · загружено 9 ноября 2026Цель, центры
-
clinmarket · № 5441 Каталог исследований · загружено 1 октября 2026Статус
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.